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Abstract 
Epstein-Barr virus positive DLBCL, NOS (EBV + 
DLBCL, NOS) occurs in apparently 
immunocompetent patients usually older than 50 
years, which can also occur in younger patients and 
has a worse prognosis than EBV negative tumors. 
EBV + DLBCL, NOS has a broader morphological 
spectrum. Here the clinicopathological of EBV 
positive DLBCL will be discussed. 
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Clinics and pathology 
Disease 
EBV+ diffuse large B-cell lymphoma (DLBCL), 
NOS was initially described by Oyama et al in 2003 
(Oyama et al, 2003). The 2008 monograph included 
"EBV-positive DLBCL of the elderly" as a 
provisional entity. These tumors occur in apparently 
immunocompetent patients usually older than 50 
years and have a worse prognosis than EBV negative 
tumors. But EBV+ DLBCL have been increasingly 
recognized in younger patients, with a broader 
morphological spectrum and better survival than 
initially thought. This new information has led to 
substitution of the modifier "elderly" with "not 
otherwise specified" (EBV+ DLBCL, NOS) in the 
updated classification (Swerdlow, et al, 2008. 
Swerdlow, et al, 2016. Nicolae A, et al, 2015. Uccini 
S, et al, 2015. Ok CY, et al. 2013). 
Phenotype/cell stem origin 
The neoplastic cells are of B-cell lineage, expressing 
the pan B-cell antigens CD19, CD20, CD22, CD79a, 
and PAX5 and are negative for pan T-cell antigents. 
Immunoglobulin light chain restriction may be 
difficult to demonstrate, except in cases with 
immunoblastic or plasmablastic features in which 
cytoplasmic Ig can be assessed. Plasmacytoid cases 
can be weakly positive or negative CD20. EBV+ 
DLBCL of the elderly usually has an ABC 
immunophenotype being MUM1/IRF41 and CD102 
and usually BCL6. BCL-2 and CD30 are usually 
positive, and CD15 is negative. It is speculated that 
either there is a change in B-cell population during 
aging or there is putative pathological specificity of 
EBV in elderly patients with DLBCL. Most cases 
displayed a striking shift to an ABC 
immunophenotype with prominent activation of NF-
kB pathway (Swerdlow, et al, 2008. Swerdlow, et al, 
2016). 
Epidemiology 
The median age of patients with EBV+ DLBCL is 
71 years (range, 50-91 years), however, younger 
patients can be affected. There is a slight male 
predominance, with a male to female ratio of 1.4 :1. 
There is a higher prevalence of EBV+ DLBCL 
among East Asians (8.7%-11.4%) compared with 
5% in Western countries. The definitive criterion for 
EBV positivity in EBV+ DLBCL remains under 
discussion (Swerdlow, et al, 2008). 
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Clinics 
EBV+ DLBCL is characterized by higher age 
distribution and an aggressive clinical course with a 
median survival of 2 years in Asian patients. Initial 
reports emphasized that EBV+ DLBCL of the 
elderly commonly involved extranodal sites. Site of 
primary extranodal involvement include the skin, 
soft tissue, bones, nasal cavity, 
pharynx/hypopharynx, tonsils, tongue, lung, pleura, 
stomach, liver, spleen, peritoneum, cecum, and bone 
marrow. Patients with EBV+ DLBCL of the elderly 
have a poorer overall survival and progression-free 
survival than patients with Activated B-cell-like 
(ABC) -type EBV-negative DLBCL in older 
European patients (Swerdlow et al, 2008). 
Pathology 
Two morphologic subtypes of EBV+ DLBCL have  
been recognized: polymorphic and monomorphic. 
Both subtypes may include large transformed cells 
or immunoblasts, as well as HRS-like giant cells and 
may demonstrate increased mitotic activity and areas 
of geographic necrosis.  
The polymorphic subtype displays a broad range of 
B-cell maturation, and lesions are composed of 
centroblasts, immunoblasts, and plasmablasts with a 
variable component of admixed reactive cells, 
including small lymphocytes, plasma cells, 
histiocytes, and epithelioid histiocytes.  
The monomorphic subtype of EBV+ DLBCL of the 
elderly is composed of monotonous sheets of large 
transformed B cells. Cases of EBV+ DLBCL of the 
elderly also can have a mixed pattern with 
intermingled polymorphic/and monomorphic areas, 
suggesting that the subtypes represent 2 ends of a 
morphologic spectrum. 
 
Figure1.  EBV+ DLBCL, polymorphic subtype. A broad range of B-cell maturation, composed of centroblasts, immunoblasts, and 
plasmablasts with a variable component of admixed reactive cells (HE staining). 
 
Figure 2.  EBV+ DLBCL, monomorphic subtype. Sheets of large transformed B cells  HE staining). 
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Figure 3.  The lymphoid cells are positive for CD20. 
 
Figure 4.  The lymphoid cells are positive for EBER (In situ hybridization). 
Treatment 
EBV+ DLBCLs, including EBV+DLBCL of the 
elderly, respond more poorly to treatment with a 
poorer outcome compared with patients who have 
EBV-negative DLBCL. Novel therapeutic 
approaches need to be considered for patients with 
EBV+ DLBCL. Possible therapeutic approaches 
include (1) EBV-specific adoptive immunotherapy; 
(2) miRNA-targeted therapy; (3) combination 
therapy based on EBV lytic phase induction 
followed by exposure of the tumor cells to 
antiherpsvirus drugs (Swerdlow et al, 2008. 
Swerdlow, et al., 2016). Less toxic treatment 
strategy such as a cell therapy for EBV-specific viral 
antigens will be needed and should be evaluated in 
clinical trials (Oyama T et al., 2007). 
Prognosis 
Young patients present with nodal disease and have 
a good prognosis (Nicolae A et al., 2015). The 
International prognostic index (IPI) and the Oyama 
score can be used for risk-stratification. The Oyama 
score includes age >70 years and presence of B 
symptoms. The expression of CD30 is emerging as a 
potential adverse, and targetable, prognostic factor 
(Castillo JJ et al., 2018).  In contrast to non-Western 
populations, the North American population had a 
low prevalence of EBV+ DLBCL that did not 
convey an adverse prognosis. A history of 
immunosuppression, while known to be a risk factor 
for the development of diffuse large B-cell 
lymphoma, did not affect subsequent prognosis 
(Tracy SI et al., 2018). 
 










Only a few genetic studies on cases of EBV+DLBCL 
have been performed. The immunoglobulin genes 
are monoclonally rearranged in most cases, with 
clonality of EBV also usually detectable using EBV 
terminal repeat regions probes and molecular 
techniques. IGH-mediated translocations are 
uncommon (15%). However, these analyses were 
restricted to single loci (IGH, IGK, IGL, PAX5, 
MYC, BCL2, and BCL6). Given the presence of a 
low number of genomic aberrations in EBV+ 
DLBCL, it has been suggested that 
immunosenescence coupled with the EBV 
oncogenic properties is sufficient, and additional 
chromosomal alterations are therefore usually not 
needed for lymphomagenesis.  
Although viral miRNA constitutes only 2% of all 
miRNA in EBV-positive DLBCL, the viral miRNAs 
share seed sequence homology with cellular 
miRNA. It also becomes evident that EBV miRNAs 
have evolved to target multiple cellular pathways 
rather than a single pathway. Interestingly, cellular 
miRNAs are modulated by viral proteins. MIR155 
has been shown in DLBCL, especially in the ABC 
subtype, and can be induced by PDLIM7 (LMP1) via 
the NF-kB pathway (Swerdlow, et al ,2008. Ok CY, 
et al. 2013).  
A study showed that the gene expression profiling 
and microRNA profiles of younger patients with 
EBV+ DLBCL is similar to older patients (Ok CY, 
et al. 2015). 
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